M. Newton

Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).

M. Socinski, Keunchil Park, P. Dennis, 2021, Clinical lung cancer.

Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC - an update from the PACIFIC trial.

Yi-long Wu, D. Planchard, C. Faivre-Finn, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.

Yi-long Wu, D. Planchard, C. Faivre-Finn, 2021 .

Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.

C. Faivre-Finn, J. Vansteenkiste, J. Naidoo, 2022, Lung cancer.

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

D. Planchard, C. Faivre-Finn, S. Senan, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PACIFIC-2: Phase 3 study of concurrent durvalumab and platinum-based chemoradiotherapy in patients with unresectable, stage III NSCLC.

L. Trani, N. Shire, J. Bradley, 2019, Journal of Clinical Oncology.

LBA49 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial

D. Planchard, C. Faivre-Finn, S. Senan, 2020 .

971TiP Phase III trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8)

A. Spira, H. Horinouchi, D. Peterson, 2022, Annals of Oncology.

Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-mutant NSCLC: A Post-Hoc Subgroup Analysis from PACIFIC.

Yi-long Wu, C. Faivre-Finn, B. Cho, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

P1.10-01 Phase 3 Study of Durvalumab Combined with Oleclumab or Monalizumab in Patients with Unresectable Stage III NSCLC (PACIFIC-9)

F. Barlesi, H. Mann, C. Aggarwal, 2022, Journal of Thoracic Oncology.

P1.18-12 PACIFIC-4/RTOG 3515: Phase III Study of Durvalumab Following SBRT for Unresected Stage I/II, Lymph-Node Negative NSCLC

J. Bradley, C. Robinson, Chen Hu, 2019, Journal of Thoracic Oncology.

Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

J. Naidoo, A. Villegas, C. Wadsworth, 2024, JTO clinical and research reports.